Search

Your search keyword '"Spohn, Simon K. B."' showing total 5 results
Start Over Author "Spohn, Simon K. B." Topic psma-pet
5 results on '"Spohn, Simon K. B."'

1. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy

Author

Adebahr, Sonja, Althaus, Alexander, Scharl, Sophia, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Lanzafame, Helena, Trapp, Christian, Koerber, Stefan A., Peeken, Jan C., Vogel, Marco M. E., Vrachimis, Alexis, Spohn, Simon K. B., Grosu, Anca-Ligia, Kroeze, Stephanie G. C., Guckenberger, Matthias, Fanti, Stefano, Hruby, George, Emmett, Louise, Belka, Claus, Schmidt-Hegemann, Nina-Sophie, Henkenberens, Christoph, Aebersold, Daniel M., Wiegel, Thomas, Afshar-Oromieh, Ali, Zamboglou, Constantinos, and Shelan, Mohamed

Published
2024
Full Text
View/download PDF

2. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml

Author

Solomonidou, Nantia, Germanou, Daphnie, Strouthos, Iosif, Karagiannis, Efstratios, Farolfi, Andrea, Koerber, Stefan A., Debus, Juergen, Peeken, Jan C., Vogel, Marco E., Vrachimis, Alexis, Spohn, Simon K. B., Shelan, Mohamed, Aebersold, Daniel, Grosu, Anca-Ligia, Ceci, Francesco, Kroeze, Stephanie G. C., Guckenberger, Matthias, Fanti, Stefano, Belka, Claus, Hruby, George, Scharl, S., Wiegel, Thomas, Bartenstein, Peter, Henkenberens, Christoph, Emmett, Louise, Schmidt-Hegemann, Nina Sophie, Ferentinos, Konstantinos, and Zamboglou, Constantinos

Published
2023
Full Text
View/download PDF

3. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis

Author

Spohn, Simon K. B., Farolfi, Andrea, Schandeler, Sarah, Vogel, Marco M. E., Ruf, Juri, Mix, Michael, Kirste, Simon, Ceci, Francesco, Fanti, Stefano, Lanzafame, Helena, Serani, Francesca, Gratzke, Christian, Sigle, August, Combs, Stephanie E., Bernhardt, Denise, Gschwend, Juergen E., Buchner, Josef A., Trapp, Christian, Belka, Claus, Bartenstein, Peter, Unterrainer, Lena, Unterrainer, Marcus, Eiber, Matthias, Nekolla, Stephan G., Schiller, Kilian, Grosu, Anca L., Schmidt-Hegemann, Nina-Sophie, Zamboglou, Constantinos, and Peeken, Jan C.

Published
2022
Full Text
View/download PDF

4. PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial.

Author

Zamboglou, Constantinos, Spohn, Simon K. B., Adebahr, Sonja, Huber, Maria, Kirste, Simon, Sprave, Tanja, Gratzke, Christian, Chen, Ronald C., Carl, Ernst Günther, Weber, Wolfgang A., Mix, Michael, Benndorf, Matthias, Wiegel, Thomas, Baltas, Dimos, Jenkner, Carolin, and Grosu, Anca L.

Subjects
*RANDOMIZED controlled trials, *PHARMACEUTICAL arithmetic, *PROSTATE-specific antigen, *RADIOSURGERY, *RADIOTHERAPY, *PROSTATE tumors
Abstract

Simple Summary: Prostate cancer (PCa) is the most diagnosed malignancy of men worldwide, and radiotherapy (RT) is a main treatment option for patients in all disease stages. Modern diagnostic imaging and RT techniques enable an effective and safe delivery of high RT doses and a reduction of treatment time. We present a study protocol of a phase III trial implementing most modern imaging techniques and RT approaches. We compare the standard RT treatment with an RT concept of reduced treatment time and focal dose escalation based on the patient's individual tumor morphology. This HypoFocal-SBRT trial aims to individualize treatment of PCa patients. Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time, and by (ii) enabling safe delivery of high RT doses. Several studies proposed a dose–response relationship for patients with primary PCa and especially in patients with high-risk features, as dose escalation leads to improved tumor control. In parallel to the improvements in RT techniques, diagnostic imaging techniques like multiparametric magnetic resonance imaging (mpMRI) and positron-emission tomography targeting prostate-specific-membrane antigen (PSMA-PET) evolved and enable an accurate depiction of the intraprostatic tumor mass for the first time. The HypoFocal-SBRT study combines ultra-hypofractionated RT/stereotactic body RT, with focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts. This novel strategy will be compared with moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide. We suspect an increase in relapse-free survival (RFS), and we will assess quality of life in order to detect potential changes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

5. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis

Author

Simon K. B. Spohn, Andrea Farolfi, Sarah Schandeler, Marco M. E. Vogel, Juri Ruf, Michael Mix, Simon Kirste, Francesco Ceci, Stefano Fanti, Helena Lanzafame, Francesca Serani, Christian Gratzke, August Sigle, Stephanie E. Combs, Denise Bernhardt, Juergen E. Gschwend, Josef A. Buchner, Christian Trapp, Claus Belka, Peter Bartenstein, Lena Unterrainer, Marcus Unterrainer, Matthias Eiber, Stephan G. Nekolla, Kilian Schiller, Anca L. Grosu, Nina-Sophie Schmidt-Hegemann, Constantinos Zamboglou, Jan C. Peeken, Spohn, Simon K B, Farolfi, Andrea, Schandeler, Sarah, Vogel, Marco M E, Ruf, Juri, Mix, Michael, Kirste, Simon, Ceci, Francesco, Fanti, Stefano, Lanzafame, Helena, Serani, Francesca, Gratzke, Christian, Sigle, August, Combs, Stephanie E, Bernhardt, Denise, Gschwend, Juergen E, Buchner, Josef A, Trapp, Christian, Belka, Clau, Bartenstein, Peter, Unterrainer, Lena, Unterrainer, Marcu, Eiber, Matthia, Nekolla, Stephan G, Schiller, Kilian, Grosu, Anca L, Schmidt-Hegemann, Nina-Sophie, Zamboglou, Constantino, and Peeken, Jan C

Subjects
Male, Prostatectomy, Personalization, Psma-pet, Risk Stratification, Suvmax, Salvage Radiotherapy, Prostate, Prostatic Neoplasms, SUVmax, Androgen Antagonists, Gallium Radioisotopes, General Medicine, Salvage radiotherapy, PSMA-PET, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Humans, Radiology, Nuclear Medicine and imaging, Neoplasm Recurrence, Local, Tomography, X-Ray Computed, Risk stratification, Retrospective Studies
Abstract

Purpose This study aims to evaluate the association of the maximum standardized uptake value (SUVmax) in positron-emission tomography targeting prostate-specific membrane antigen (PSMA-PET) prior to salvage radiotherapy (sRT) on biochemical recurrence free survival (BRFS) in a large multicenter cohort. Methods Patients who underwent 68 Ga-PSMA11-PET prior to sRT were enrolled in four high-volume centers in this retrospective multicenter study. Only patients with PET-positive local recurrence (LR) and/or nodal recurrence (NR) within the pelvis were included. Patients were treated with intensity-modulated-sRT to the prostatic fossa and elective lymphatics in case of nodal disease. Dose escalation was delivered to PET-positive LR and NR. Androgen deprivation therapy was administered at the discretion of the treating physician. LR and NR were manually delineated and SUVmax was extracted for LR and NR. Cox-regression was performed to analyze the impact of clinical parameters and the SUVmax-derived values on BRFS. Results Two hundred thirty-five patients with a median follow-up (FU) of 24 months were included in the final cohort. Two-year and 4-year BRFS for all patients were 68% and 56%. The presence of LR was associated with favorable BRFS (p = 0.016). Presence of NR was associated with unfavorable BRFS (p = 0.007). While there was a trend for SUVmax values ≥ median (p = 0.071), SUVmax values ≥ 75% quartile in LR were significantly associated with unfavorable BRFS (p = 0.022, HR: 2.1, 95%CI 1.1–4.6). SUVmax value in NR was not significantly associated with BRFS. SUVmax in LR stayed significant in multivariate analysis (p = 0.030). Sensitivity analysis with patients for who had a FU of > 12 months (n = 197) confirmed these results. Conclusion The non-invasive biomarker SUVmax can prognosticate outcome in patients undergoing sRT and recurrence confined to the prostatic fossa in PSMA-PET. Its addition might contribute to improve risk stratification of patients with recurrent PCa and to guide personalized treatment decisions in terms of treatment intensification or de-intensification. This article is part of the Topical Collection on Oncology—Genitourinary.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results